Theravance Biopharma (TBPH) Total Current Liabilities (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Total Current Liabilities data on file, last reported at $31.8 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 0.87% year-over-year to $31.8 million in Q1 2026; TTM through Mar 2026 was $31.8 million, a 0.87% increase from a year earlier, with the FY2025 full-year figure at $38.3 million, up 19.38% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $31.8 million, down from $38.3 million in the prior quarter.
• Over the last five years, Total Current Liabilities for TBPH reached as high as $142.1 million in Q3 2022 and fell as low as $21.7 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $37.8 million across 5 years, with a median of $31.5 million in 2025.
• Across the five-year window, Total Current Liabilities slumped 82.15% in 2023 and surged 138.09% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $28.7 million in 2022, then fell by 13.75% to $24.8 million in 2023, then increased by 29.55% to $32.1 million in 2024, then grew by 19.38% to $38.3 million in 2025, then slipped by 17.04% to $31.8 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $31.8 million in Q1 2026, $38.3 million in Q4 2025, and $37.4 million in Q3 2025.